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Background: Cardiac resynchronization therapy (CRT) and implantable
cardioverter-defibrillators (ICD) are effective therapies for heart failure (HF)
patients with cardiac dyssynchrony. Patients receiving primary prevention
CRT-D that positively remodel may no longer qualify for ICD indication due
to CRT induced left ventricular ejection fraction (LVEF) improvement. 
Objective: We aimed to evaluate the outcome of CRT-D patients at the
time of device replacement (DR). Methods: Patients undergoing primary pre-
vention CRT-D DR were prospectively included from November 2007 to
March 2011 in two centers. CRT response was as a ≥1 NYHA class improve-
ment and an increase in LVEF≥10%. Six months before DR, all patients
underwent echocardiography and device interrogation. Patients without theo-
retical ongoing ICD indication (TOII) at DR were defined as those with
LVEF≥40% without appropriate ICD therapy (AT) during the first ICD ser-
vice-life. 
Results: A total of 107 consecutive patients were enrolled. Sixty-one
patients (57%) were considered CRT responders after the index procedure. At
the time of DR (56.4±14.4 months from initial implant), 87% of CRT
responders were free of AT, compared with 70% of non CRT-responders
(p=0.02). Thirty-nine patients (36%) did not meet the criteria for TOII. During
follow-up (mean 26.4±14.4 months after DR) 37 patients (95%) without TOII
were free of AT versus 49 of 68 patients (72%) with ongoing TOII (p=0.007).
By multivariable analysis the only independent predictor of AT after DR was
TOII (hazard ratio=6.43;p=0.01).
Conclusion: Absence of theoretical ICD indication occurs in more than
one third of CRT-D patients undergoing DR. In addition AT rate is relatively
low (2.2%/year) in this subgroup of patients.
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Safety and effectiveness of transvenous lead extraction in octogenarians. 
Introduction: As the median population ages, the number of elderly
patients with implantable cardiac devices referred for transvenous lead extrac-
tion will dramatically increase. The safety and effectiveness of lead extraction
in elderly patients has not been well evaluated. We report the safety and effec-
tiveness of transvenous lead extraction in octogenarians.
Methods and results: From January 2002 to December 2013, we reviewed
data from consecutive patients more than 80 years referred to our institution
for transvenouslead extraction for infection or lead dysfonction.
Clinical characteristics, procedural features, and periprocedural major and
minor complications were compared between octogenarians and younger
patients. Out of 391 patients undergoing lead extraction during the study
period, 100 (25,6%) patients were octogenarians (mean age 84,24 years; range
80-98; 75 % males).
A significantly higher percentage of octogenarians presented with chronic
renal failure (P=0,03), history of malignancy ( P =0,04)
Infection was the most common reason for lead extraction in elderly (82%
of cases).Laser assistance for extraction was recquired in 69 elderly patients
(69%)
Complete lead extraction efficacy were similar between both groups (99%
in octogenarians vs 98,6% in patients <80 years; P =0,6).
No deaths occurred in the octogenarian group. No differences in terms of
other periprocedural major and minor complications were found between the
2 groups. 
Conclusion: Despite a significantly higher rate of comorbidities, transve-
nouslead extraction can be performed safely and successfully in octogenarians
with a low rate of complications 
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Purpose: Remote monitoring (RM) is now accepted as a safe alternative
to standard follow-up (sFU) for ICD.
Methods: We analyzed the long term arrhythmic events and device-related
outcomes of 843 ICD/CRT-D.
Patients (pts) were equipped with Boston (44%), Medtronic (40%), St Jude
Medical (11%), Biotronik (3%) and Sorin (2%) RM systems. FU started after
hospital discharge. Automatic FU with RM was performed every 3 months,
with at least one sFU /year. In emergency cases, pts were invited for in-
hospital control visits.
ICDs were programmed with 2 zones (VT zone >180 bpm / VF zone
>220bpm). All RM alerts and related EGMs as well as the reasons of therapies
were reviewed by two physicians.
Results: 843 pts (82% male, 64±10 y.o.) were enrolled. 52% had ischemic
cardiomyopathy, 44% previous history of AF. 63% were primary prevention
ICDs. CRT (46%) and dual chamber (44%) were mainly represented, single
chamber 10%.
During a FU period of 28±14 months, we noted 16±11 automatic RM FU
and 2±1 sFU visits/patient. 87 pts died during FU. 92 pts had major alerts (37
for ICD lead dysfunction, 33 for ERI reached, 18 for electrical storm, 4 the-
rapies off). Within 216 pts with minor alerts, 112 refer to AF, with for 54 pts
early detection of unknown AF resulting in therapy modifications. 
238 appropriate (app) shocks occurred in 73 pts (9%). 57 inappropriate
shocks occurred in 23 pts (3%) and were mainly due to AF (61%, other: sinus
tachycardia 9%, lead dysfunction 13%, T oversensing 9%, electromagnetic
interference 4%).
141 pts had app ATP (17% of the population). 14 pts with high LV lead
impedance detected by RM had LV lead dislodgement and underwent early
intervention.
Conclusion: In a large single center observational study, RM has demon-
strated to be an effective method of FU for ICD recipients. Early diagnoses of
AF or lead failure allow rapid management of patients and are associated with
a very low rate of inappropriate shocks. 
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Background: The life-saving benefit of implantable cardioverter defibril-
lators (ICD) has been well demonstrated, and therefore their utilization has
considerably grown in the last 10 years. At the same time, complications have
become an increasingly important concern.
Objectives: This study aimed to assess the prevalence and impact on out-
comes (late complications and overall mortality) of early complications after
ICD implantation for primary prevention in a large French population.
© Elsevier Masson SAS. All rights reserved.
 
62 Archives of Cardiovascular Diseases Supplements (2015) 7, 58-75
Methods: From a multicentric French registry (DAI-PP Registry, 2002-
2012), 5547 consecutive patients, with coronary artery disease or dilated car-
diomyopathy, were implanted with an ICD in the setting of primary preven-
tion. From 5338 (96%) patients with full information, we determined
prevalence, independent associated factors and prognosis of the occurrence of
early (within 30 days post implantation) complications. 
Results: Early complications occurred in 709 patients (13.5%), mainly
related to lead dysfunction or hematoma (56%). Independent associated fac-
tors to early complications were renal impairment (clearance <30ml/min,
OR=1.69, 95% CI 1.19-2.41, P<0.001), cardiac resynchronization therapy
(OR=1.61, 95% CI 1.17-2.21, P=0.004), anticoagulant therapy (OR=1.30,
95% CI 1.04-1.63, P=0.02) and older age (OR=1.02, 95% CI 1.01-1.02,
P=0.03). During a mean follow-up of 3.1±2.3 years, 834 patients experienced
≥1 complication (15.6%), mainly inappropriate therapies and/or lead dysfunc-
tion (75%). After consideration of potential confounding factors, early compli-
cations were significantly associated with the occurrence of late complications
(OR=2.15, 95% CI 1.73-2.66, P<0.0001) and a higher risk of overall mortality
(OR=1.48, 95% CI 1.17-1.88, P=0.001).
Conclusions: Early complication is a frequent event after ICD implantation
occurring in one out of six patients. These events are associated with a signif-
icant increase of late complications and overall mortality. 
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Few data on therapeutic management of patients over 80 years with non-
valvular atrial fibrillation (AF) are available in general population. 
Objectives: The objectives of the AF-S.AGES cohort (Sujets AGÉS) were
to describe real-life therapeutic management of non-institutionalized elderly
subjects with AF according to age groups, i.e., 65-79 and ≥80 years and to
determine factors associated with anticoagulant treatment.
Methods: General practitioners recruited 1072 patients aged ≥65 years old
between 2009 and 2011. General characteristics were first evaluated in the
overall sample and according to age groups and use of anticoagulant treatment
at inclusion. 
Results: Mean age was 78.0 (SD 6.5) years and 42% were older than
80 years. In the overall sample, 19% of patients had paroxysmal AF, 15% per-
sistent, 56% permanent and for 10% AF type was unknown. Vitamin K anta-
gonists (VKA) were used in 77% of patients, antiplatelet therapy in 17% and
12% of patients did not receive any antithrombotic treatment. There were no
differences between age-groups (< 80 or ≥80 years) for VKA (78 vs. 76%,
p=0.58). Rate control drugs were more frequently used (55%) than rhythm
control drugs (37%). Class I and class II antiarrhythmic drugs were less often
used in octogenarians than in younger patients (5.6% vs. 12.3%, p<0.001 and
36 vs. 41%, p<0.05). Among patients ≥80 years old, VKA use was associated
with permanent AF younger age and cancer. Among patients < 80 years old,
the use of VKA was associated with permanent AF and preserved functional
autonomy. HAS-BLED and HEMORR2HAGES scores were associated with
non-use of VKA in subjects ≥80 and < 80 years, CHADS2 and CHA2DS2-
VASc scores were not associated with VKA use in both groups.
Conclusions: We observed a higher use of anticoagulant therapy in elderly
AF outpatients even after 80 years when compared with previous studies.
These results suggest that recent international guidelines are better imple-
mented in the elderly population. 
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Purpose of the study: to evaluate the role of the mechanism of paroxysmal
supraventricular tachycardia (SVT) on the incidence of spontaneous atrial
fibrillation (AF). The relation between SVT and AF is well-known but its fre-
quency could depend on the mechanism of SVT.
Methods: 1559 patients, mean age 49±19 years, with SVT and without
anterograde conduction over an accessory pathway (AP) were referred for
electrophysiological study (EPS), performed in control state and after isopro-
terenol. 
Results: SVT was related to atrioventricular nodal re-entrant tachycardia
(AVNRT) in 1262 patients (group I), either typical (n=1180)(group IA) or
atypical (n=183)(group IB). In 297 patients SVT was related to atrioventric-
ular re-entrant tachycardia (AVRT) due to a concealed AP (group II). At the
initial evaluation 47 group I patients (4%)(44 of group IA, 4%, 3 of group IB,
2%), 6 of group II (2%) had presented at least one episode of sustained AF
(NS). During follow-up (mean 3±2 years), 97 patients developed AF, 86 of
group I (7%)(71 of group IA, 6%, 15 of group IB, 8%),11 of group II (4%).
AF risk was higher in group I than in group II (p<0.045); differences remain
significant for group IA/IB. When patients with AF at first study were
excluded AF risk was similar in all groups: 5% of group I)(4% of group IA;
6.5% of group IB)(0.06) and 3% of group II. Ablation of slow pathway/AP
was performed in 1099 patients, 67% of group I (69% of group IA, 51% of
group IB), 64% of group II (NS). AF risk was paradoxically higher in patients
in whom ablation was performed in group I (6.7% in group I, 7% in group IA,
13% in group IB), compared to patients without ablation (4% in group I, 4%
in group IA, 3% in group IB)(p<0.022) and was unchanged in group II (4%
after ablation and 3% in patients without ablation).
Conclusions: AF-related SVT was rare (3%), independent on the mecha-
nism of SVT. The risk of subsequent AF after a follow-up of 3 years increased
to 6% and was near 5% in patients without AF at initial evaluation; it was
only higher in patients with atypical AVNRT than in patients with AVRT. The
risk was not affected by the ablation of the slow pathway or the AP. 
0173
Is oral anticoagulation needed in patients with atrial fibrillation, stent
implantation and low-moderate risk of stroke? 
Laurent Fauchier (1), Francisco Marin (2), Christophe Saint Etienne (1),
Juan Miguel Ruiz Nodar (3), Fabrice Ivanes (1), Sergio Manzano-Fernan-
dez (2), Denis Angoulvant (1), Mariano Valdes (2), Greg Lip (4)
(1) CHU Trousseau, Cardiologie, Tours, France – (2) Hospital Universi-
tario Virgen de la Arrixaca, Murcia, Espagne – (3) Hospital General
Universitario, Alicante, Espagne – (4) University of Birmingham, Cardio-
vascular medicine, Birmingham, Royaume-Uni
Thromboprophylaxis for patients with coronary artery disease and atrial
fibrillation (AF) is an issue when patients undergo intracoronary stent place-
ment and several recent guidelines propose slightly different management. 
Methods: All patients with AF and stent implantation seen between 2000
and 2010 in 3 academic hospitals were identified in a database and followed
up for mortality, stroke and bleeding events.
Results: Among all patients seen between 2000-2010, 343 had AF, coro-
nary stent placement and CHADS2 score=0 or 1. In these patients, OAC was
